Celgene Corporation (NASDAQ: CELG) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $1 billion of the Company's common stock through December 2012. This authorization is in addition to the $500 million authorization announced on January 10, 2011. The $500 million program announced in April of 2009 has been fully utilized.
Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene's management and in accordance with the requirements of the Securities and Exchange Commission. As of December 31, 2010, Celgene had 470,388,164 shares of common stock outstanding.